Get the Stockscreener App
37.70
1.11%
0.395
Royalty Pharma Plc stock is traded at $37.70, with a volume of 2.96M.
It is up +1.11% in the last 24 hours and up +4.56% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$37.30
Open:
$37.06
24h Volume:
2.96M
Relative Volume:
0.78
Market Cap:
$16.30B
Revenue:
$2.31B
Net Income/Loss:
$1.66B
P/E Ratio:
16.41
EPS:
2.297
Net Cash Flow:
$827.02M
1W Performance:
+3.58%
1M Performance:
+4.56%
6M Performance:
+14.67%
1Y Performance:
+38.66%
1-Day Range:
$36.76
$38.09
1-Week Range:
$36.23
$38.09
52-Week Range:
$24.05
$38.09
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
37.70 | 16.12B | 2.31B | 1.66B | 827.02M | 2.297 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.41 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
629.07 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
424.19 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.14 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.80 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Royalty Pharma stock hits 52-week high at 38.01 USD - Investing.com
Royalty Pharma acquires AMVUTTRA royalty interest for $310 million - Investing.com
Royalty Pharma Acquires $310 Million Royalty Interest in Alnylam's AMVUTTRA from Blackstone Life Sciences - Quiver Quantitative
Royalty Pharma acquires AMVUTTRA royalty for $310 million - StreetInsider
Royalty Pharma (NASDAQ: RPRX) acquires 1% AMVUTTRA royalty for $310M from Blackstone - Stock Titan
Is Royalty Pharma plc reversing from oversold territory2025 Market Outlook & Capital Efficient Trade Techniques - newser.com
Quantitative breakdown of Royalty Pharma plc recent moveTrade Signal Summary & Real-Time Stock Price Movement Reports - newser.com
Corton Capital Inc. Acquires New Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Can Royalty Pharma plc stock rebound after recent weaknessEarnings Miss & Consistent Profit Trading Strategies - newser.com
Applying chart zones and confluence areas to Royalty Pharma plcMarket Performance Report & Fast Gain Swing Trade Alerts - newser.com
Royalty Pharma PLC $RPRX Shares Purchased by Strs Ohio - MarketBeat
Is Royalty Pharma plc (RPD) stock attractive post correctionExit Point & Consistent Return Investment Signals - newser.com
How Royalty Pharma plc (RPD) stock performs in easing cyclesForecast Cut & Long-Term Growth Plans - newser.com
What To Expect From Royalty Pharma’s (RPRX) Q3 Earnings - Yahoo! Finance UK
Royalty Pharma PLC $RPRX is Torray Investment Partners LLC's 3rd Largest Position - MarketBeat
Tredje AP fonden Increases Stake in Royalty Pharma PLC $RPRX - MarketBeat
Will Royalty Pharma plc (RPD) stock maintain strong growthPortfolio Return Report & Community Trade Idea Sharing - newser.com
Will Royalty Pharma plc (RPD) stock hit Wall Street targetsJobs Report & Weekly Breakout Opportunity Watchlist - newser.com
Is Royalty Pharma plc stock a top momentum playWeekly Stock Report & Weekly Setup with High ROI Potential - newser.com
What the charts say about Royalty Pharma plc today2025 Price Momentum & Scalable Portfolio Growth Methods - newser.com
Why Royalty Pharma plc (RPD) stock could outperform next year2025 Technical Overview & Safe Entry Trade Signal Reports - newser.com
Why Royalty Pharma plc (RPD) stock could rally stronglyStock Surge & Long-Term Safe Investment Plans - newser.com
What MACD signals say about Royalty Pharma plcMarket Movement Recap & Low Risk Investment Opportunities - newser.com
8,849 Shares in Royalty Pharma PLC $RPRX Acquired by MMA Asset Management LLC - MarketBeat
Royalty Pharma PLC $RPRX is Regal Partners Ltd's 9th Largest Position - MarketBeat
Top chart patterns to watch in Royalty Pharma plcStock Surge & Risk Managed Investment Strategies - newser.com
Is Royalty Pharma plc stock a safe investment in uncertain marketsWeekly Loss Report & Reliable Intraday Trade Plans - newser.com
Royalty Pharma plc : Close to an important technical resistance levels - MarketScreener
Why analysts remain bullish on Royalty Pharma plc stockEarnings Trend Report & AI Enhanced Trading Alerts - newser.com
Historical volatility pattern of Royalty Pharma plc visualizedLong Setup & Risk Controlled Swing Alerts - newser.com
Can Royalty Pharma plc stock beat analyst upgradesProfit Target & Fast Gain Swing Trade Alerts - newser.com
Detecting support and resistance levels for Royalty Pharma plcMarket Trend Report & Fast Entry Momentum Alerts - newser.com
28,646 Shares in Royalty Pharma PLC $RPRX Bought by Nisa Investment Advisors LLC - MarketBeat
How Royalty Pharma Prints Cash Without Biotech's Biggest Risks - MSN
Using Python tools to backtest Royalty Pharma plc strategiesMarket Trend Report & Stock Portfolio Risk Control - newser.com
Royalty Pharma (NASDAQ:RPRX) Upgraded by Wall Street Zen to "Buy" Rating - MarketBeat
What drives Royalty Pharma plc stock priceMarket Sentiment Extremes & Low Risk Trading Ideas - earlytimes.in
Royalty Pharma PLC $RPRX Shares Purchased by Fjarde AP Fonden Fourth Swedish National Pension Fund - MarketBeat
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.77%
0.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):